Biotechnology company Alzheon Inc. has raised $50 million in new venture capital to complete clinical trials of a potential oral medication for Alzheimer’s disease.
Framingham, Mass.-based Alzheon is testing the drug in late-stage, Phase 3 clinical trials. The company, which plans to complete enrollment of the 300-person study this year, expects to have data from the trial in 2024, Chief Executive Martin Tolar said.
